BBS-related obesity can be partly related to impaired MC4R pathway activity; thus, in 2022, the FDA extended the use of setmelanotide for chronic weight management in adult and pediatric patients ≥ 6 years of age with BBS [245]. This evidence concerns the gene MC4R and Bardet-Biedl syndrome.